Adagene to Participate in Two Investor Conferences in September

Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies, utilizing computational biology and artificial intelligence to address unmet patient needs [3][4] - The company has established strategic collaborations with global partners to leverage its SAFEbody precision masking technology [3] Technology and Pipeline - Adagene's proprietary Dynamic Precision Library (DPL) platform includes NEObody™, SAFEbody, and POWERbody™ technologies, which are designed to enhance the safety and efficacy of antibody therapeutics [4] - The SAFEbody technology specifically targets the tumor microenvironment, allowing for tumor-specific antibody targeting while minimizing toxicity to healthy tissues [4] Clinical Programs - The lead clinical program, ADG126 (muzastotug), is a masked anti-CTLA-4 SAFEbody currently in phase 1b/2 clinical studies, focusing on Metastatic Microsatellite-stable (MSS) Colorectal Cancer in combination with anti-PD-1 therapy [5] - The SAFEbody platform is validated for use across various antibody-based therapeutic modalities, including Fc empowered antibodies and antibody-drug conjugates [5] Investor Engagement - Adagene's Chief Strategy Officer will participate in one-on-one investor meetings and a fireside chat at two upcoming investor conferences in New York in September [1][2] - Webcasts of the presentations will be available on the company's website for at least 30 days [2]